Results from the company’s Talapro-2 trial saw a 38% reduction in the risk of death among HRR-mutated patients.

SAN DIEGO, Jan. 21, 2025 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect ...

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY – Get Free Report) has earned a consensus recommendation of “Buy” from the seven research firms that are currently covering the stock, Marketbeat Ratings reports ...

It costs money to maintain the various facilities, utilities and personnel that allow scientists to conduct research in the ...

Highlights,ARS Pharmaceuticals (SPRY) has received favorable market target projections from research experts.,Significant ...

Oppenheimer initiated coverage of ARS Pharmaceuticals (SPRY) with an Outperform rating and $40 price target As the first and only approved ...

ARS Pharmaceuticals launched Neffy, the first FDA-approved needle-free epinephrine nasal spray for severe allergic reactions.

ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and caregivers ...

Laura Shawver, a director at ARS Pharmaceuticals Inc. (NASDAQ:SPRY), has sold 50,000 shares of common stock, according to a recent filing with the Securities and Exchange Commission. The shares were ...

EST ARS Pharmaceuticals (SPRY) files automatic mixed securities shelfInvest with Confidence: Follow TipRanks' Top Wall Street Analysts to ...

Investing.com - ARS Pharmaceuticals (NASDAQ: SPRY) reported first quarter EPS of $-0.16, $0.03 worse than the analyst estimate of $-0.13. Revenue for the quarter came in at $20K... ByInvesting.com ...

Overview: ARS Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing treatments for severe allergic reactions with a market cap of approximately $1.39 billion. Operations: The ...